Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Scleroderma Clear all
Suspended Phase 2 Interventional
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
10 mg/kg CM-101, Placebo
Drug
Lead sponsor
ChemomAb Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 21, 2026, 7:39 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
16
States / cities
Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 7:39 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
TEPEZZA, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced May 21, 2026, 7:39 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Scleroderma, Pulmonary Artery Hypertension
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 21, 2026, 7:39 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Scleroderma
Interventions
Internet-based self-management program, Scleroderma book
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced May 21, 2026, 7:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced May 21, 2026, 7:39 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Systemic Sclerosis-associated Interstitial Lung Disease
Interventions
Abituzumab 1500 mg, Abituzumab 500 mg, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced May 21, 2026, 7:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
Interventions
MQX-503
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Timeline
2006
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 29, 2007 · Synced May 21, 2026, 7:39 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
Interventions
Belumosudil (KD025), Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Scleroderma
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Plerixafor, Quality-of-Life Assessment, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Imatinib mesylate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced May 21, 2026, 7:39 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Refractory Autoimmune Diseases
Interventions
BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
Genetic · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 21, 2026, 7:39 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
Interventions
German manufactured UVA1 emitting light system
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced May 21, 2026, 7:39 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Interventions
FT819, Fludarabine, Cyclophosphamide, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
13
States / cities
Fullerton, California • Irvine, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Morphea
Interventions
Crisaborole
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced May 21, 2026, 7:39 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Scleroderma
Interventions
Hematopoietic stem cell transplantation
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Cyclophosphamide, Mesna, G-CSF, Leukopheresis, Total Body Irradiation
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced May 21, 2026, 7:39 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 21, 2026, 7:39 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2007 · Synced May 21, 2026, 7:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Scleroderma
Interventions
Optical Elastography, Visual Assessment
Device · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced May 21, 2026, 7:39 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
Interventions
KYV-101, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
David Porter
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 7:39 PM EDT